Mission Therapeutics granted MHRA Clinical Trial Authorisation (CTA) for MTX325 for the treatment of Parkinson’s Disease
- Company on-track to dose first participant in multi-part, adaptive Phase 1, first-in-human study in healthy volunteers and Parkinson’s Disease (PD) patients in the first quarter of 2024
- CTA comes as Nature Reviews Drug Discovery hails Mission’s mitophagy approach as “an appealing disease-modifying therapeutic strategy” for PD
Cambridge, UK – 5 December 2023 – Mission Therapeutics (“Mission” or the “Company”), a clinical-stage biotech developing first-in-class therapeutics targeting mitophagy, today announces that the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has granted clinical trial authorisation (CTA) for Mission to commence its multi-part, adaptive Phase 1, first-in-human study evaluating the safety and tolerability of MTX325, intended for the treatment of Parkinson’s Disease (PD).
